AbbVie has announced a landmark $10.9 billion acquisition of Apogee Therapeutics, a strategic move poised to significantly fortify the biopharmaceutical…
Read More
Voro Therapeutics and Alloy Therapeutics Forge Strategic Partnership to Revolutionize Tumour-Selective T-Cell Engager Therapies
Voro Therapeutics and Alloy Therapeutics have announced a significant strategic research partnership aimed at developing a new generation of masked…
Read More
Vedana Therapeutics Secures $46 Million Series A to Advance Next-Generation Migraine Prevention Therapies Targeting PACAP
Seattle-based biotech firm Vedana Therapeutics has successfully closed a $46 million Series A financing round, a significant infusion of capital…
Read More
AvenCell Therapeutics Unveils Promising Early Data for Switchable Allogeneic CAR-T Therapy in Relapsed/Refractory AML at EHA 2026
AvenCell Therapeutics presented updated results for its CAR-T cell blood cancer therapy at EHA 2026. The European Hematology Association (EHA)…
Read More
Eli Lilly and Ascidian Therapeutics Forge Strategic Alliance to Pioneer Novel Genetic Medicines for Kidney Diseases
Eli Lilly and Company, a global pharmaceutical leader, has significantly bolstered its commitment to the cutting-edge field of genetic medicines…
Read More
Eli Lilly and Ascidian Therapeutics Forge Strategic Alliance to Revolutionize Kidney Disease Treatment Through Advanced Genetic Medicine
Eli Lilly and Company has announced a significant research collaboration and licensing agreement with Ascidian Therapeutics, a pioneering biotechnology firm…
Read More
Autobahn Therapeutics Secures FDA Fast Track Designation for Elunetirom in Bipolar Depression
Autobahn Therapeutics has announced a significant milestone in its development of elunetirom, a novel central nervous system (CNS)-directed thyroid hormone…
Read More
Bayer Acquires Perfuse Therapeutics for Up to $2.45 Billion to Bolster Ophthalmology Pipeline with Novel Endothelin Receptor Antagonist
Bayer AG is set to significantly expand its presence in the ophthalmology market with the acquisition of Perfuse Therapeutics, a…
Read More
UCB Acquires Candid Therapeutics for Up to $2.2 Billion to Bolster Autoimmune Disease Pipeline with Novel T-Cell Engagers
UCB’s strategic move to acquire Candid Therapeutics for an initial $2 billion upfront, with an additional $200 million in milestone…
Read More
BioMarin Pharmaceutical Finalizes $4.8 Billion Acquisition of Amicus Therapeutics, Bolstering Rare Disease Portfolio
BioMarin Pharmaceutical has officially concluded its substantial acquisition of Amicus Therapeutics, a move that promises to significantly expand BioMarin’s footprint…
Read MoreYOU MAY HAVE MISSED
